- United Kingdom
- /
- Healthtech
- /
- AIM:INS
An Intrinsic Calculation For Instem plc (LON:INS) Suggests It's 29% Undervalued
Key Insights
- The projected fair value for Instem is UK£11.56 based on 2 Stage Free Cash Flow to Equity
- Current share price of UK£8.25 suggests Instem is potentially 29% undervalued
- Our fair value estimate is 13% higher than Instem's analyst price target of UK£10.22
Does the August share price for Instem plc (LON:INS) reflect what it's really worth? Today, we will estimate the stock's intrinsic value by taking the expected future cash flows and discounting them to their present value. We will take advantage of the Discounted Cash Flow (DCF) model for this purpose. Models like these may appear beyond the comprehension of a lay person, but they're fairly easy to follow.
Companies can be valued in a lot of ways, so we would point out that a DCF is not perfect for every situation. If you still have some burning questions about this type of valuation, take a look at the Simply Wall St analysis model.
See our latest analysis for Instem
The Method
We're using the 2-stage growth model, which simply means we take in account two stages of company's growth. In the initial period the company may have a higher growth rate and the second stage is usually assumed to have a stable growth rate. In the first stage we need to estimate the cash flows to the business over the next ten years. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.
A DCF is all about the idea that a dollar in the future is less valuable than a dollar today, so we discount the value of these future cash flows to their estimated value in today's dollars:
10-year free cash flow (FCF) estimate
2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | |
Levered FCF (£, Millions) | UK£7.32m | UK£10.2m | UK£12.0m | UK£13.6m | UK£14.9m | UK£16.0m | UK£16.9m | UK£17.6m | UK£18.2m | UK£18.7m |
Growth Rate Estimate Source | Analyst x3 | Analyst x3 | Est @ 18.26% | Est @ 13.20% | Est @ 9.65% | Est @ 7.17% | Est @ 5.43% | Est @ 4.22% | Est @ 3.37% | Est @ 2.77% |
Present Value (£, Millions) Discounted @ 7.1% | UK£6.8 | UK£8.9 | UK£9.8 | UK£10.4 | UK£10.6 | UK£10.6 | UK£10.5 | UK£10.2 | UK£9.8 | UK£9.4 |
("Est" = FCF growth rate estimated by Simply Wall St)
Present Value of 10-year Cash Flow (PVCF) = UK£97m
We now need to calculate the Terminal Value, which accounts for all the future cash flows after this ten year period. The Gordon Growth formula is used to calculate Terminal Value at a future annual growth rate equal to the 5-year average of the 10-year government bond yield of 1.4%. We discount the terminal cash flows to today's value at a cost of equity of 7.1%.
Terminal Value (TV)= FCF2033 × (1 + g) ÷ (r – g) = UK£19m× (1 + 1.4%) ÷ (7.1%– 1.4%) = UK£332m
Present Value of Terminal Value (PVTV)= TV / (1 + r)10= UK£332m÷ ( 1 + 7.1%)10= UK£168m
The total value, or equity value, is then the sum of the present value of the future cash flows, which in this case is UK£265m. The last step is to then divide the equity value by the number of shares outstanding. Compared to the current share price of UK£8.3, the company appears a touch undervalued at a 29% discount to where the stock price trades currently. Remember though, that this is just an approximate valuation, and like any complex formula - garbage in, garbage out.
Important Assumptions
Now the most important inputs to a discounted cash flow are the discount rate, and of course, the actual cash flows. You don't have to agree with these inputs, I recommend redoing the calculations yourself and playing with them. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Instem as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 7.1%, which is based on a levered beta of 0.965. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.
SWOT Analysis for Instem
- Earnings growth over the past year exceeded the industry.
- Currently debt free.
- No major weaknesses identified for INS.
- Annual earnings are forecast to grow faster than the British market.
- Trading below our estimate of fair value by more than 20%.
- Revenue is forecast to grow slower than 20% per year.
Next Steps:
Although the valuation of a company is important, it ideally won't be the sole piece of analysis you scrutinize for a company. DCF models are not the be-all and end-all of investment valuation. Instead the best use for a DCF model is to test certain assumptions and theories to see if they would lead to the company being undervalued or overvalued. For instance, if the terminal value growth rate is adjusted slightly, it can dramatically alter the overall result. What is the reason for the share price sitting below the intrinsic value? For Instem, we've compiled three essential elements you should assess:
- Risks: We feel that you should assess the 1 warning sign for Instem we've flagged before making an investment in the company.
- Future Earnings: How does INS's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.
- Other Solid Businesses: Low debt, high returns on equity and good past performance are fundamental to a strong business. Why not explore our interactive list of stocks with solid business fundamentals to see if there are other companies you may not have considered!
PS. The Simply Wall St app conducts a discounted cash flow valuation for every stock on the AIM every day. If you want to find the calculation for other stocks just search here.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About AIM:INS
Instem
Instem plc, together with its subsidiaries, provides information technology solutions and services to the life sciences healthcare market worldwide.
Proven track record with adequate balance sheet.